Pancreatic cancer is commonly associated with activating mutations in the oncogene KRAS (mutated in over 90% of all PDAC cases) as well as mutations in the tumor suppressors TP53, SMAD4 and CDKN2A/p16 [43]. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.